Intesa Sanpaolo completes new round in ongoing share buyback programme

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo announced it has executed a series of share buyback transactions between 28 July and 1 August 2025. The initiative is part of the bank’s previously disclosed programme to purchase its own shares for annulment, which began on 2 June 2025 after being announced on 26 May.

According to the bank, Morgan Stanley Europe SE acted as the third-party intermediary responsible for carrying out the transactions independently and without involvement from Intesa Sanpaolo Group. The purchases took place on Euronext Milan, managed by Borsa Italiana.

During this period, Intesa Sanpaolo acquired a total of 2,521,692 shares. This represents about 0.01% of its share capital. The average price paid per share was €5.0248, with a total transaction value amounting to €12,670,997.96.

The company stated: “With reference to the execution of the programme of purchase of own shares for annulment (buyback), which was disclosed to the market on 26 May 2025 and launched on 2 June 2025, Intesa Sanpaolo, pursuant to applicable regulations, communicates that – on the basis of information provided by Morgan Stanley Europe SE, the third-party intermediary appointed to execute the programme in full independence and without any involvement of the Intesa Sanpaolo Group – from 28 July to 1 August 2025 the Bank executed the purchase transactions summarised in the table below on the regulated market Euronext Milan managed by Borsa Italiana.”

The buyback forms part of broader efforts by European banks to manage their capital structures through share repurchases or similar programmes.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.